Clinical Trials Directory

Trials / Completed

CompletedNCT01294163

Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery

Efficacy and Safety of Xenon Anaesthesia Compared to Sevoflurane Anaesthesia and Total Intravenous Anaesthesia for On-pump Coronary Artery Bypass Graft Surgery: a Randomised, Three-arm, Single-blind, International Study

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
509 (actual)
Sponsor
Air Liquide Santé International · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Xenon is a gaseous anaesthetic agent registered in several European countries. It has been administered safely during cardiac surgery in pilot studies. In animal studies, xenon decreases the size of experimental myocardial infarction. This 3-arm study will compare xenon, sevoflurane and a propofol-based total intravenous anaesthesia for maintenance of anaesthesia during coronary artery bypass graft surgery conducted with extra-corporeal circulation. Xenon and sevoflurane will be administered before and after extracorporeal circulation. Propofol will be administered during extracorporeal circulation in the three groups of patients. The study will compare the postoperative myocardial damage observed 24 hours after surgery from blood levels of troponin I, a largely accepted biomarker of myocardial necrosis. The main hypothesis is that the myocardial damage observed after xenon administration will not be superior to the damage observed after sevoflurane administration (non-inferiority). The second hypothesis is that the myocardial damage observed after xenon administration will be inferior to the damage observed after total intravenous anaesthesia.

Conditions

Interventions

TypeNameDescription
DRUGXenonInhaled xenon, maximal inspired concentration of 65%.
DRUGSevofluraneInhaled sevoflurane, maximal inspired concentration of 1.8%.
DRUGPropofolHourly dose of 2-4 mg/kg

Timeline

Start date
2011-04-01
Primary completion
2014-04-01
Completion
2014-04-01
First posted
2011-02-11
Last updated
2015-12-21
Results posted
2015-12-21

Locations

17 sites across 4 countries: France, Germany, Italy, Netherlands

Source: ClinicalTrials.gov record NCT01294163. Inclusion in this directory is not an endorsement.